LGNGoldman’s still in the bull camp
Goldman Sachs analyst Adam Bubes kept the Buy rating on Legence (LGN) and lifted the price target to $72 from $63. That’s a clean little 14% reset higher, which is analyst-speak for: “we still like this thing, and maybe even more than before.”
Why you should care
When a big-name bank raises its target on a stock that’s already trading around $69.54, it usually means the Street thinks the next leg up isn’t fantasy-land stuff. Legence is now sitting pretty close to that new target, so the call is more of a confidence check than a moonshot promise.
But it’s not all confetti
The article also flags a few yellow lights:
- GF Score: 24/100, which is basically the financial equivalent of “could do better.”
- Insider selling of $1.66 billion over the last three months, which can make investors raise an eyebrow or three.
- A forward P/E of 54.58, meaning the market is paying up for future growth and expecting the story to keep improving.
Big picture
This is a classic Wall Street tug-of-war: one hand says Legence has enough growth juice to justify a higher target, while the other hand says the valuation and insider selling deserve a closer look. For investors, the takeaway is simple — Goldman’s still constructive, but the stock is priced like expectations are already doing push-ups.